PTC Therapeutics, Inc. (NASDAQ:PTCT) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
PTC Therapeutics, Inc. (NASDAQ:PTCT) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
PTC Therapeutics, Inc. (NASDAQ:PTCT) shareholders are probably feeling a little disappointed, since its shares fell 2.8% to US$31.29 in the week after its latest second-quarter results. The results don't look great, especially considering that statutory losses grew 23% toUS$1.29 per share. Revenues of US$187m did beat expectations by 3.1%, but it looks like a bit of a cold comfort. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
PTC Therapeutics公司(NASDAQ:PTCT)的股東們可能會感到有點失望,因爲在最新的第二季度業績公佈後的一週內,其股票下跌了2.8%至31.29美元。 結果並不理想,特別是考慮到其目前每股虧損增加了23%,達到了1.29美元。18700萬美元的營收雖然超過了3.1%的預期,但似乎只是稍微安慰了一點而已。 這是股東跟蹤公司業績的重要時期,他們可以在報告中看到公司的表現,了解專家對明年的預測,並查看業務期望是否有任何變化。因此,我們彙集了最新的法定預測,以查看分析師對明年的預期。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240811/0-1afbf8f1aab4aaf4ffc802ca30dfe0c7-0-891eb59be2a6026b13b64b38ee380439.png/big)
Taking into account the latest results, the eleven analysts covering PTC Therapeutics provided consensus estimates of US$740.8m revenue in 2024, which would reflect an uncomfortable 18% decline over the past 12 months. Losses are supposed to decline, shrinking 17% from last year to US$5.18. Before this latest report, the consensus had been expecting revenues of US$743.4m and US$5.22 per share in losses.
最新業績的考慮下,覆蓋PTC Therapeutics的十一個分析師提供了2024年74080萬美元的營收的一致估計,反映了過去12個月18%的不舒適下降。虧損預計將下降,從去年的5.18美元下降17%至美元。在此最新報告之前,一致預期的營收爲74340萬美元,虧損爲每股5.22美元。
The consensus price target was unchanged at US$38.50, suggesting that the business - losses and all - is executing in line with estimates. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values PTC Therapeutics at US$64.00 per share, while the most bearish prices it at US$26.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.
共識價格目標保持不變,爲38.5美元,表明該業務 - 虧損和所有其他 - 正在按照預期執行。同時,看一下分析師的估計範圍可能也非常有幫助,以判斷離群者的意見與平均意見有多不同。目前,最看好的分析師將PTC Therapeutics股票價格估計爲每股64.00美元,而最看淡的分析師將其價格定在26.00美元。請注意分析師價格目標之間的巨大差距?這對我們來說意味着這家公司的潛在情景有相當廣泛的範圍。
Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that revenue is expected to reverse, with a forecast 32% annualised decline to the end of 2024. That is a notable change from historical growth of 25% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 23% annually for the foreseeable future. It's pretty clear that PTC Therapeutics' revenues are expected to perform substantially worse than the wider industry.
當然,觀察這些預測的另一種方法是對行業本身進行對比。我們需要指出,預計營收將出現逆轉,年化下降32%至2024年底。這與過去五年25%的歷史增長相比,是一個值得注意的變化。相比之下,我們的數據表明,同行業內(有分析師覆蓋)的其他公司預計在可預見的未來將年增長23%。很明顯,PTC Therapeutics的營收預計要比整個行業表現得差得多。
The Bottom Line
最重要的事情是分析師增加了它對下一年每股虧損的估計。令人欣慰的是,營收預測未發生重大變化,業務仍有望比整個行業增長更快。共識價格目標穩定在28.50美元,最新估計不足以對價格目標產生影響。
The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
最顯而易見的結論是,分析師們對明年的虧損預測沒有做出任何改變。好消息是,營收預測也沒有發生重大變化;儘管預測表明其預期表現將不如整個行業。投資者請注意,共識價格目標沒有發生實質性改變,這表明該業務的內在價值在最新的估計中沒有經歷任何重大變化。
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for PTC Therapeutics going out to 2026, and you can see them free on our platform here.
接下來,我們認爲公司的長期前景比明年的收益更重要。我們對PTC Therapeutics的預測到2026年,並且您可以在此免費查看他們。
Plus, you should also learn about the 3 warning signs we've spotted with PTC Therapeutics (including 1 which is a bit unpleasant) .
此外,您還應該了解我們發現的PTC Therapeutics的3個警告信號(其中1個有點不愉快)。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。